Institutional members access full text with Ovid®

Share this article on:

Infliximab in the Treatment of Severe Recalcitrant Hidradenitis Suppurativa and Concomitant Rheumatoid Arthritis: A Case Study

Ward, Muriel

Journal of the Dermatology Nurses' Association: March/April 2012 - Volume 4 - Issue 2 - p 129–132
doi: 10.1097/JDN.0b013e31824ab96f
Case Report

ABSTRACT A 52-year-old man presents to a private dermatology clinic with a history of severe recalcitrant hidradenitis suppurativa (HS) and concomitant rheumatoid arthritis. The patient is an active duty master sergeant in the U.S. Army and has just relocated for a permanent change of station to active drilling reservist status. He is motivated to continue managing his HS with infliximab, and he wishes to explore insurance coverage. Although not indicated for treating HS, infliximab may be a viable option for severe recalcitrant HS. The following case study presents the history, assessment and plan, treatment, evaluation, and discussion highlighting important points regarding the use of a biological agent in severe recalcitrant HS and concomitant rheumatoid arthritis.

Muriel Ward, MS, ANP-c, University of South Florida, Tampa, Florida.

The author declares no conflict of interest.

Correspondence concerning this article should be addressed to Muriel Ward, MS, ANP-c, College of Nursing, 2901 Bruce B. Downs Blvd., MDC Box 22, University of South Florida, Tampa, FL 33612. E-mail:

© 2012 Lippincott Williams & Wilkins, Inc.